Galderma Labora Patent-Cliff Exposure & CMS Drug Spending Portfolio

Galderma Labora (US): 2 reconciled FDA prescription therapies, $5K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$5K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$5K
California HCAI SB 17 Filings1 WAC filings (max 21.2% 2-yr change)